AHA 2016: Update on Lipid Lowering Therapies
This CME program will focus on new and emerging therapeutic options in the management of patients with dyslipidemia that were discussed at the American Heart Association Annual Congress 2016 in New Orleans, Louisiana. The expert faculty will evaluate clinical trial data and the responsiveness to therapeutic agents. They will discuss the science behind new and emerging therapies, the efficacy and safety data supporting these therapies, and the role of new therapies alongside traditional dyslipidemia treatment options.
This activity has been designed to meet the educational needs of cardiologists and other healthcare professionals responsible for the diagnosis, treatment or management of patients with dyslipidemia.
Upon completion of this activity, participants will be able to:
- Describe guidelines consensus for LDL-C goal for dyslipidemia patients.
- Examine outcomes data of PCSK9 inhibitors presented at AHA 2016.
- Integrate new data into individualized treatment plans to improve outcomes and lower the risk of cardiovascular events for patients with dyslipidemia.
James Underberg, MD
Marc Sabatine, MD
Michael Koren, MD
Joyce L. Ross, MSN, CRNP, CCS, FNLA, FPCNA
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
James Underberg, MD
Consultant/Advisor: Aegerion Pharmaceuticals Inc.; Akcea Therapeutics; Amarin Corp.; The American Society for Preventive Cardiology; Amgen Inc.; Invitae Corporation; National Lipid Association.; Recombine;
Grant/Research Support: Pfizer Inc.; Aegerion Pharmaceuticals Inc.
Speaker's Bureau: Alexion; Amgen Inc.; AstraZeneca; Genzyme Corporation; Merck & Co., Inc.; New Haven Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; sanofi- aventis U.S. LLC
Marc Sabatine, MD
Consultant/Advisor: Abbott; Amgen Inc.; AstraZeneca; Critical Diagnostics; Daiichi Sankyo Company, Limited; Esai Co., Ltd.; Gilead; GlaxoSmithKline; F. Hoffmann-La Roche Ltd; Intarcia Therapeutics, Inc.; Merck & Co., Inc.; sanofi- aventis U.S. LLC; Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support: Amgen Inc.; Alnylam Pharmaceuticals, Inc.; AstraZeneca; Cubist Pharmaceuticals; Intarcia Therapeutics, Inc.; Merck & Co., Inc.; MyoKardia; ZEUS Scientific, Inc.
|Michael Koren, MD||Nothing to Disclose|
|Joyce Ross, CRNP, MSN|
Consultant/Advisor: Amarin Pharma Inc.; Kaneka Americas Holding Inc.Speaker's Bureau: AbbVie Inc.; Amarin Pharma Inc.; Amgen Inc.; Akcea Therapeutics; Kowa Pharmaceuticals America, Inc.; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC
Non-faculty: Timothy Hayes, MD, PhD; Emma Gilmartin; Nicole Brestowski; Megan Gentile; Sandy Breslow; Alison Kemp; Leah Johnson; and Bernard M. Adams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
This CME activity has been supported by an independent educational grant from Amgen, Inc.
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.
CME Credit (Physicians)
The Elsevier Office of Continuing Medical Education is accredited by the Acceditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME, and Amgen, Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician